The pharmaceutical community is abuzz with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s showing significant promise in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a more substantial decrease in body weight and benefit metabolic health, partic